Nomura Y, Tashiro H, Hisamatsu K
Department of Breast Surgery, National Kyushu Cancer Center Hospital, Fukuoka, Japan.
J Natl Cancer Inst. 1990 Jul 4;82(13):1146-9. doi: 10.1093/jnci/82.13.1146.
Of 534 human primary breast cancers provided for clonogenic assay in vitro, 276 (51.7%) developed distinctive colony formation by the soft-agar method. Estrogen receptors (ERs) were assayed by dextran-coated charcoal methods. A total of 65 (23.7%) of 274 breast cancers responded to added 10 nM 17 beta-estradiol (E2) by an increase in the number of colonies per dish of 150% or more of that in the controls treated with dextran-coated charcoal. The ER-positive and ER-negative tumors differed significantly in their response to E2: 55 (29.9%) of 184 ER-positive tumors responded versus 10 (11.1%) of 90 ER-negative tumors. The cancers in which the number of colonies increased to 150% or more of that of the controls were considered to be estrogen dependent; those in which the number of colonies increased to less than 150% of the control values were considered to be estrogen independent. When 1 microM tamoxifen (TMX) was added to the medium, 48 (21.3%) of 225 cancers showed a decreased in the number of colonies to 50% or less of that of the controls. Thus, we could separate breast cancers that were TMX sensitive (No. of colonies less than or equal to 50% of that of controls) from those that were TMX resistant (No. of colonies greater than 50% of that of controls). The response to TMX of the ER-positive cancers was significantly higher than that of the ER-negative tumors: 39 (25.5%) of 153 ER-positive tumors responded versus nine (12.5%) of 72 ER-negative tumors. In 153 ER-positive and 71 ER-negative tumors, we evaluated the correlation between the response to E2 and the response to TMX. ER-positive and ER-negative tumors differed significantly in their sensitivities to the two drugs. The TMX sensitivity did not completely correlate with the E2 dependence.(ABSTRACT TRUNCATED AT 250 WORDS)
在用于体外克隆形成试验的534例人原发性乳腺癌中，276例（51.7%）通过软琼脂法形成了独特的集落。采用葡聚糖包被活性炭法检测雌激素受体（ERs）。在274例乳腺癌中，共有65例（23.7%）对添加的10 nM 17β-雌二醇（E2）有反应，每皿集落数增加至对照组（用葡聚糖包被活性炭处理）的150%或更多。ER阳性和ER阴性肿瘤对E2的反应有显著差异：184例ER阳性肿瘤中有55例（29.9%）有反应，而90例ER阴性肿瘤中有10例（11.1%）有反应。集落数增加至对照组150%或更多的癌症被认为是雌激素依赖性的；集落数增加至对照组值不到150%的癌症被认为是雌激素非依赖性的。当向培养基中添加1 μM他莫昔芬（TMX）时，225例癌症中有48例（21.3%）集落数减少至对照组的50%或更少。因此，我们可以将对TMX敏感的乳腺癌（集落数小于或等于对照组的50%）与对TMX耐药的乳腺癌（集落数大于对照组的50%）区分开来。ER阳性癌症对TMX的反应显著高于ER阴性肿瘤：153例ER阳性肿瘤中有39例（25.5%）有反应，而72例ER阴性肿瘤中有9例（12.5%）有反应。在153例ER阳性和71例ER阴性肿瘤中，我们评估了对E2的反应与对TMX的反应之间的相关性。ER阳性和ER阴性肿瘤对这两种药物的敏感性有显著差异。TMX敏感性与E2依赖性并不完全相关。（摘要截断于250字）
